Related Experiment Videos
Isoprinosine and NPT 15392: immunomodulation and cancer
Advances in Experimental Medicine and Biology
|January 1, 1983
Abstract:
These data demonstrate that both Isoprinosine and NPT 15392 are active nontoxic biological response modifiers that qualify for studies in cancer patients. Because of their immunomodulating properties, these agents are expected to be most appropriate in the treatment of immunosuppressed patients who are prone to infection or recurrence following cytoreductive therapy.
Insights
Isoprinosine and NPT 15392 are safe and effective biological response modifiers for cancer patients. Their immune-boosting properties make them ideal for treating immunosuppressed individuals prone to infection or cancer recurrence.
Area of Science:
- Immunology
- Pharmacology
- Oncology
Background:
- Immunosuppression is a common complication in cancer patients, increasing susceptibility to infections and disease recurrence.
- Biological response modifiers (BRMs) offer a therapeutic strategy to enhance the host immune system against cancer.
- Isoprinosine and NPT 15392 are novel compounds with potential immunomodulatory effects.
Purpose of the Study:
- To evaluate the efficacy and safety of Isoprinosine and NPT 15392 as biological response modifiers.
- To determine the suitability of these agents for clinical trials in cancer patients.
- To explore their potential application in managing immunosuppression in cancer therapy.
Main Methods:
- Preclinical studies were conducted to assess the biological activity of Isoprinosine and NPT 15392.
- Toxicity assessments were performed to ensure the safety profile of the compounds.
- Immunomodulatory effects were analyzed to understand their mechanism of action.
Main Results:
- Both Isoprinosine and NPT 15392 demonstrated significant biological activity.
- The agents were found to be nontoxic at effective doses.
- Data confirmed their potent immunomodulating properties.
Conclusions:
- Isoprinosine and NPT 15392 are promising nontoxic biological response modifiers.
- These agents are well-suited for further investigation in cancer patient studies.
- Their immunomodulatory capabilities suggest significant potential in treating immunosuppressed cancer patients, particularly for preventing infection and recurrence after therapy.